Evidence map›Paper›PMID 29024570›Full record

ArticleThe FEBS journal2017

Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease.

Ahmed Elharram, Nicole M Czegledy, Michael Golod, Ginger L Milne, Erik Pollock, Brian M Bennett, Mikhail S Shchepinov

Open access · greenAbstract read
In one paragraph

Article in The FEBS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Deuterated Polyunsaturated Fatty Acids AlleviatebioRxiv : the preprint server for biology · 2025
    Article
  7. Aberrant Mitochondrial Metabolism in Alzheimer's Disease Links Energy Stress with Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  8. Journal of the American Chemical Society · 2025
    Article
  9. Review
  10. In defence of ferroptosis.Signal transduction and targeted therapy · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ahmed ElharramDepartment of Biomedical & Molecular Sciences and Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, Kingston, Canada.
Nicole M CzegledyDepartment of Biomedical & Molecular Sciences and Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, Kingston, Canada.
Michael GolodDepartment of Biomedical & Molecular Sciences and Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, Kingston, Canada.
Ginger L MilneDivision of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA.
Erik PollockStable Isotope Laboratory, University of Arkansas, Fayetteville, AR, USA.
Brian M BennettDepartment of Biomedical & Molecular Sciences and Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, Kingston, Canada.
Mikhail S ShchepinovRetrotope, Inc., Los Altos, CA, USA.
Queen's University · CARetrotope (United States) · USUniversity of Arkansas at Fayetteville · USVanderbilt University · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI POWERS, ALVIN C · 1986 to 2011
$28.1M
Novel Imaging Biomarker for Treating Spatial Memory Loss in Prodromal Alzheimer's Disease ModelsR01AG058171 · NIA · WAYNE STATE UNIVERSITY · PI BENNETT, BRIAN M, BERKOWITZ, BRUCE A. · 2017 to 2021
$2.8M
CIHR 395023NIA NIH HHS R01 AG058171NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P60 DK020593
6 · The paper itself

Abstract

Oxidative damage resulting from increased lipid peroxidation (LPO) is considered an important factor in the development of late onset/age-related Alzheimer's disease (AD). Deuterium-reinforced polyunsaturated fatty acids (D-PUFAs) are more resistant to the reactive oxygen species-initiated chain reaction of LPO than regular hydrogenated (H-) PUFAs. We investigated the effect of D-PUFA treatment on LPO and cognitive performance in aldehyde dehydrogenase 2 (Aldh2) null mice, an established model of oxidative stress-related cognitive impairment that exhibits AD-like pathologies. Mice were fed a Western-type diet containing either D- or H-PUFAs for 18 weeks. D-PUFA treatment markedly decreased cortex and hippocampus F

Indexed as

Aldehyde Dehydrogenase, MitochondrialAlzheimer DiseaseAnimalsCognitionDeuteriumDisease Models, AnimalF2-IsoprostanesFatty Acids, UnsaturatedHippocampusHumansHydrogenationLipid PeroxidationMemoryMice, KnockoutAldehyde Dehydrogenase, MitochondrialALDH2 protein, mouseDeuteriumF2-IsoprostanesFatty Acids, UnsaturatedAlzheimer's diseasecognitiondeuterium-based therapeuticslipid peroxidationpolyunsaturated fatty acid

Identifiers

PMID29024570
PMCPMC5716852
OpenAlexW2761877473

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.